No Data
No Data
Express News | Gyre Therapeutics Announces Nmpa Approval for Clinical Trial Evaluating Pirfenidone Capsules in Oncology-Related Pulmonary Complications
We Think You Should Be Aware Of Some Concerning Factors In Gyre Therapeutics' (NASDAQ:GYRE) Earnings
Gyre Therapeutics Announces Publication of Protocol for Phase 3 Trial on F351
Is Gyre Therapeutics, Inc.'s (NASDAQ:GYRE) ROE Of 18% Impressive?
Gyre Therapeutics Reports Strong Turnaround in 2024 Earnings
Noble Financial Maintains Gyre Therapeutics(GYRE.US) With Buy Rating, Maintains Target Price $20